Arbutus Biopharma (ABUS) Research & Development (2013 - 2026)

Arbutus Biopharma has disclosed Research & Development across 14 years of filings, most recently posting $4.1 million for Q1 2026.

• Research & Development for Q1 2026 came in at $4.1 million, down 54.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.4 million (down 57.13% YoY), and the FY2025 annual result was $25.2 million, down 53.29% from the prior year.
• Research & Development came in at $4.1 million for Q1 2026 at Arbutus Biopharma, down from $5.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $22.9 million in Q4 2022 to a low of $4.1 million in Q1 2026.
• The 5-year median for Research & Development is $15.6 million (2024), against an average of $14.2 million.
• Across the five-year window, Research & Development soared 45.21% in 2022 and slumped 64.65% in 2025, its largest moves.
• Arbutus Biopharma's Research & Development stood at $22.9 million in 2022, then decreased by 23.47% to $17.6 million in 2023, then slumped by 49.84% to $8.8 million in 2024, then sank by 43.18% to $5.0 million in 2025, then retreated by 17.7% to $4.1 million in 2026.
• The last three Research & Development figures came in at $4.1 million (Q1 2026), $5.0 million (Q4 2025), and $5.8 million (Q3 2025), per Business Quant data.